Ratos (RATO) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
8 Jul, 2026Executive summary
Earnings and profitability increased despite subdued and uncertain market conditions, supported by efficiency initiatives, cost control, and non-recurring gains such as a SEK 300m arbitration award related to Diab.
Net sales for Q3 2025 were SEK 4,165m, down 9% year-over-year, while adjusted EBITA rose 31% to SEK 373m and profit for the period reached SEK 444m.
Cash flow from operations improved to SEK 868m from SEK 277m, supported by legal settlements and structural changes.
Operational focus remains on efficiency, cost control, and leveraging synergies from integrations and automation projects.
Financial highlights
Adjusted EBITA margin increased to 9.0% from 6.2% year-over-year, with EBITDA up over 30% and adjusted EPS rising to 0.43.
Organic growth was -3% for the quarter, mainly due to a 12% decline in construction and services, while product solutions grew 3% organically.
Cash flow for the quarter more than tripled year-over-year, and operating profit was SEK 606m, up from a loss of SEK 25m.
Net working capital as a percentage of LTM net sales was 8.2%.
Outlook and guidance
Market remains uncertain but shows early signs of recovery, with expectations of stabilization in automotive consultancy demand in early 2026.
No specific forecasts provided for Q4 due to project timing and weather dependencies, especially in construction and services.
Continued focus on operational improvements, cost reductions, and margin enhancement, particularly in underperforming units.
Latest events from Ratos
- Q2 2026 delivered 3.4% organic growth, 14% EBITA rise, and strong cash flow.RATO
Q2 202617 Jul 2026 - Adjusted EBITDA/EBITA up 32% with strong order intake and Plantasjen turnaround.RATO
Q1 20259 Jul 2026 - Adjusted EBITA/EBITDA rose 21% on 3.4% organic growth, with a new strategy and strong liquidity.RATO
Q1 20264 May 2026 - Adjusted EBITA rose 17% to SEK 1,931m, with improved leverage and major restructuring.RATO
Q4 20254 Mar 2026 - Earnings and margins improved despite 9% lower sales, with strong order intake and cash flow.RATO
Q2 20243 Feb 2026 - Strong cash flow and stable earnings offset sales decline amid major restructuring.RATO
Q3 202419 Jan 2026 - Adjusted EBITA rose, but non-recurring items from Plantasjen led to lower reported profit.RATO
Q4 202423 Dec 2025 - Margin expansion and major capital gains achieved amid challenging market conditions.RATO
Q2 202516 Nov 2025